PB Fintech Target Cut 31% by Nomura as IRDAI Commission Caps Loom

Another downgrade, but with a way back up

Nomura has become the latest brokerage to cut its view on PB Fintech, the company behind Policybazaar and Paisabazaar. It lowered its target price by about 31%, from ₹1,590 to ₹1,100, and kept its "neutral" rating.19 What sets this note apart from the other cuts is its structure. It is titled "What if...?" and, alongside the lower base case, it lays out two scenarios that put fair value between ₹1,335 and ₹1,366.92

The reason for the cut is no secret. On September 23, the Insurance Regulatory and Development Authority of India (IRDAI) released a consultation paper on reforming insurance distribution. It proposed tighter limits on insurers' management expenses and commission cuts of between one-half and two-thirds across health, term and motor insurance.6 The paper would also ban "dark patterns" on insurance websites, such as making customers hand over personal details before they can see product features or prices.2

For a company built on online lead generation, that second proposal may matter as much as the commission caps. In our view, Nomura's note is less about the number and more about how far a fintech intermediary's value depends on decisions made by the regulator.

Inside Nomura's base case

Nomura assumes PB Fintech leaves its point-of-sales-person (POSP) business, the channel that sells through agents. It leaves Policybazaar, the Dubai operation and the corporate segment unchanged in its model.79 It also resets take rates, meaning the share of premium PB Fintech keeps as revenue, to match the proposed caps. It assumes the company responds with deep cuts to spending: total expenses fall 40% in FY28 and 48% in FY29.9

The result is a severe hit to earnings. Premium estimates drop 13% for FY28 and 19% for FY29. Net profit estimates fall 72% and 51% for the same two years.27 Nomura expects EBITDA margin to fall to 7.9% in FY28 and then recover to 18.2% in FY29.9 In its discounted-cash-flow model, long-run revenue growth for FY26–50 drops to 13.2% a year from 15.1%.29

The reports do not agree on one detail. Some describe that growth figure as covering FY26–2030,6 while the Financial Express quotes Nomura directly as "FY26-50F".7 The longer period is the more credible reading, because a DCF valuation depends on decades of cash flows.

At ₹1,100, Nomura's target values the stock at about 70 times September 2028 earnings and 40 times September 2029 earnings.9 Reports also differ on the upside from current levels. CNBC-TV18, measuring from the ₹1,040 close on October 7, put it at about 5.8%.6 The Financial Express, using a lower intraday price of ₹1,012, put it at about 9%.7 Either way, Nomura is not telling clients to buy into the sell-off.

Two ways to a higher value

The first scenario assumes the regulator raises the proposed health-insurance commission cap by 2 percentage points. That rests on PB Fintech's argument that it helps customers when they are discharged from hospital, which improves their experience.7 In that case, Nomura's revenue estimates rise by 3 and 4 percentage points for FY28 and FY29, and net profit rises 37% and 19% above the base case. Fair value becomes ₹1,335, or 41 times September 2029 earnings.29

The second scenario has Policybazaar start selling traditional savings insurance products. These would make up only 0.5–1.1% of total premiums in FY28–29.9 Net profit would be 5–6 percentage points above the base case, long-run revenue growth would rise by 80 basis points, and fair value would reach ₹1,366, or 46 times September 2029 earnings.79

The first scenario is the more revealing. It shows that a 2-point change in one product's commission cap is worth more than ₹230 per share in Nomura's model. When a small regulatory adjustment moves a valuation that much, the stock is effectively a bet on the regulator's final decision.

Analysts agree on the damage, not on the outcome

Nomura is the latest of several brokerages to cut targets in quick succession. HSBC was early: it downgraded the stock to "hold" and cut its target from ₹2,100 to ₹1,150. It also lowered its FY28 and FY29 earnings-per-share estimates by 56% and 17%.17 Motilal Oswal kept a "neutral" rating with a ₹1,150 target. It estimated that FY28 core online insurance revenue could fall about 30%. Without savings elsewhere, that would cut earnings by 46%. Reducing staff and advertising costs by 20% would limit the cut to about 30%.14 Macquarie also downgraded the stock to neutral with a ₹1,150 target.18

Bernstein made the biggest cut. It reduced its target by 53%, from ₹2,310 to ₹1,085, only days after reaffirming the higher figure, but kept its "outperform" rating.13 Its note, titled "Max pain", argued that the lower take rates in general insurance cannot cover PB Fintech's current costs. It also called the next 18 months "do-or-die".11 Bernstein removed POSP revenue from its model entirely, calling that business low-margin and no longer viable. It also dropped its two-stage DCF model and now values the company at about 25 times FY30 earnings.1116

Jefferies remains the most optimistic. It cut its target from ₹2,050 to ₹1,540 but kept a "buy" rating.12 The company has indicated that the value of its non-life business could fall to 33–40% of its original level if the health and motor commission cuts go ahead.412 Even so, Jefferies initially left earnings unchanged and cut its valuation multiple by 30%, to 18 times FY30 EBITDA, citing uncertainty over take rates. BofA Securities has a neutral rating and a ₹1,410 target. It considers the impact on Policybazaar's life and term insurance business manageable and sees room to gain market share.

The split is clear. All of these analysts accept that FY28 will be very difficult. The two outliers disagree on what comes after: Bernstein still rates the stock "outperform" but assumes no regulatory relief at all, while Jefferies stays bullish on the core business. Nomura sits between them, with a cautious base case and modelled upside if the regulator softens its rules.

What the stock has already priced in

The stock has fallen hard. PB Fintech dropped 36% on September 24, the day after the draft came out, erasing more than ₹31,000 crore of market value.14 It fell about 48% over seven straight sessions.6 On October 1 it went below its 2021 IPO price of ₹980, wiping out five years of gains, and hit a 52-week low of ₹965.612 It then recovered about 6% over two sessions, slipped again on the day Nomura's note came out, and rose about 2.5% to around ₹1,020 the following day.69

Nomura's ₹1,100 target is close to Bernstein's ₹1,085 and the ₹1,150 set by HSBC, Motilal Oswal and Macquarie. That points to a rough agreement that today's price already reflects most of a worst-case outcome.

Why it matters for fintech

The wider issue is the business model. Policybazaar grew by turning online searches for insurance into sales calls, backed by a large call-centre operation. Moneycontrol Hindi reported that the draft explicitly prohibits collecting contact details to generate quotes, and that the proposed take rates may not cover call-centre costs.18 If those rules survive, a large part of the customer funnel will have to be rebuilt.

The company's response so far has been to stress the after-sale service it provides. It says it handled more than 375,000 insurance claims in FY26, of which 245,000 were health claims.8 Nomura's first scenario turns that argument into a valuation by assuming the regulator rewards that service with a higher commission cap.7 Management has also said it will cut marketing spending and slow hiring rather than make mass layoffs.

None of the brokerages quoted here says that automation or AI will solve the problem. Still, the arithmetic leads in that direction. When revenue per policy is capped, the only lever left is the cost of serving each customer, and PB Fintech can no longer gather leads by requiring personal details before showing prices. Nomura's assumed cuts of 40–48% in expenses show how much efficiency analysts now expect.9 The consultation paper is also a warning to other Indian fintech distributors: margins earned by standing between products and consumers are only as secure as the regulator allows them to be.

The final rules will matter more than any brokerage model. Jefferies has noted that the consultation paper could change after feedback.2 Until IRDAI decides, the scenarios in Nomura's note serve as a measure of how much value depends on the outcome.